Brain-Computer Interfaces Go Clinical: What Neuralink and Rivals Have Achieved

The First Patients Are Typing With Their Thoughts

In January 2024, Neuralink implanted its N1 chip in a human patient for the first time. By mid-2026, five patients have received the device, and the results, while preliminary, have been striking. Noland Arbaugh, the first recipient, a quadriplegic since a diving accident, can now control a computer cursor, play video games, browse the web, and type at speeds exceeding 30 words per minute using thought alone. The second and third patients have shown similar capabilities, with one using the interface to operate a robotic arm with enough precision to pick up a glass of water.

How the N1 Chip Works

The N1 is about the size of a coin and sits flush with the skull after a section of bone is removed by a surgical robot called R1. A flexible array of 1,024 electrodes, each thinner than a human hair, is threaded into the motor cortex, the brain region that plans and executes movement. These electrodes detect the electrical activity of individual neurons as the patient thinks about moving. An onboard processor decodes these signals in real time and transmits them wirelessly to a nearby computer. The Gut-Brain Axis: How Your Digestive System Influences Mental Health covers the broader landscape of neurotechnology research. The key innovation is the thread design: flexible polymer electrodes cause far less brain tissue damage than the rigid silicon probes used in earlier brain-computer interfaces like BrainGate.

Competitors Are Not Standing Still

Neuralink gets the headlines, but it is not alone. Synchron, an Australian-American company, has implanted its Stentrode device in multiple patients using a far less invasive approach: the device is delivered through the jugular vein and lodged in a blood vessel adjacent to the motor cortex, requiring no open brain surgery at all. Blackrock Neurotech has been making implantable electrode arrays for research for over two decades and is pursuing its own clinical pathway. Precision Neuroscience, founded by a Neuralink co-founder, is developing a thin-film electrode array that sits on the brain surface rather than penetrating it. Each approach trades off signal quality against surgical risk.

Beyond Paralysis: The Broader Vision

Restoring communication and movement to paralyzed patients is the immediate clinical application, and it is genuinely life-changing for those patients. But the technology’s ambitions extend much further. Neuralink has stated its long-term goal is a “general-purpose brain interface” that healthy people could use to interact with computers at the speed of thought. Antibiotic Resistance: The Silent Pandemic Threatening Modern Medicine examines how emerging technologies intersect with societal questions. Depression treatment through targeted brain stimulation, memory enhancement, and direct brain-to-brain communication are all theoretically possible with advanced enough interfaces, though each raises profound ethical questions.

Safety Concerns and Setbacks

The path has not been smooth. After Arbaugh’s implant, some electrode threads retracted from the brain tissue, reducing signal quality. Neuralink modified the surgical technique for subsequent patients and reported better thread retention. The company also faced scrutiny over its animal testing program, with former employees and the USDA raising concerns about the pace and conditions of primate experiments. Long-term biocompatibility remains an open question: Will the brain’s immune response gradually encapsulate the electrodes in scar tissue, degrading performance over months or years? Only extended follow-up will answer this.

The Regulatory Landscape

The FDA granted Neuralink breakthrough device designation, which accelerates the review process but does not lower the safety bar. Each additional patient implant requires FDA authorization. The path to broader commercial availability likely involves years of clinical trials with hundreds of patients. For now, the technology remains strictly investigational, limited to patients with severe motor disabilities who have exhausted other options. But the pace of progress in 2025-2026 suggests that brain-computer interfaces will become a routine clinical tool within the coming decade, at least for patients with neurological conditions.